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Despite advances in antimicrobial therapy, better
supportive care modalities, and the use of a wide
range of preventive measures, hospital-acquired
infections continue to be important causes of
morbidity and mortality. Advances in the ﬁeld of
hospital infection management were explored at a
symposium entitled ‘Optimising outcomes of
hospital infections through appropriate empiric
antimicrobial therapy’ at the 17th European Con-
gress of Clinical Microbiology and Infectious
Diseases in Munich, Germany, on 1 April 2007.
The speciﬁc aims of the symposium were to
present relevant ﬁndings and concepts regarding:
(i) the evolving microbiology of resistant bacterial
pathogens, including methicillin-resistant Staphy-
lococcus aureus (MRSA) and important Gram-
negative pathogens; (ii) the clinical and
pharmaco-economic impact of inappropriate anti-
microbial therapy in an environment of increasing
resistance and patient complexities; (iii) current
and emerging strategies for managing today’s
prevalent bacterial infections in hospitalised
patients; and (iv) new and emerging therapies
for the management of resistant pathogens.
The presentations detailed in this supplement
can be summarised as follows. Jean Chastre, of
the Groupe Hoˆpital Pitie´-Salpeˆtrie`re in Paris,
explained that conditions in intensive care units
are particularly conducive to the emergence of
resistance, and this resistance is not uniform in
its geographical distribution. He discussed the
clinical implications of the increasing prevalence
of MRSA as well as the increasing rates of
antimicrobial resistance seen in other Gram-
positive and Gram-negative pathogens, and
presented recommendations for appropriate
antimicrobial stewardship to achieve optimal
efﬁcacy in managing today’s resistant patho-
gens. Peter Davey, from the University of
Dundee, deﬁned ‘inappropriate’ antimicrobial
therapy as either ineffective against the causa-
tive pathogen or effective but delayed by the
time that elapsed before effective therapy was
started. They showed that inappropriate treat-
ment is common in today’s clinical setting and
is associated with a greater risk of adverse
clinical outcomes, including increased overall
treatment costs. Davey described several com-
puterised decision-support systems that are
being developed to help clinicians identify the
optimal approaches to antimicrobial treatment
in their hospitals. Yehuda Carmeli, from the Tel
Aviv Sourasky Medical Center, discussed the
clinical impact of today’s problematic bacterial
pathogens, particularly noting the virulence
associated with Panton–Valentine leukocidin,
which is now found in many MRSA strains.
He also suggested treatment strategies that
incorporate empirical therapy, noting the risks
of delaying appropriate empirical therapy.
Finally, Philippe Moreillon, from the University
of Lausanne, focused on the mechanisms by
which S. aureus acquires resistance to the pen-
icillins and how the emerging resistance of
S. aureus to vancomycin, ﬁrst seen in the USA
and now documented worldwide, underscores
the continuing need for antimicrobial agents
that counter these new mechanisms. Stressing
the ongoing need for new classes of antimicro-
bial agents, Moreillon further described the
target mechanisms and properties of several
recently approved agents and others in late
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stages of development for the treatment of
MRSA.
These presentations stimulated lively and inter-
esting discussions on the present situation and
the future of antimicrobial treatments. The main
theme of the presentations was the importance
of treating serious bacterial infections quickly
with empirical antimicrobial therapy. We look
forward to further interesting developments in
this ﬁeld.
 2008 The Author
Journal Compilation European Society of Clinical Microbiology and Infectious Diseases, CMI, 14 (Suppl. 3), 1–2
2 Introduction
